Skip to content

Study to Evaluate the Efficacy and Safety of Wound Healing Topical Spray in Patients with Diabetic Foot Ulcer.

A Randomized, Parallel, Multi-center, Double Blind, Double Arm, Comparative, Pilot Study to Evaluate the Efficacy and Safety of Wound Healing Topical Spray in Patients with Diabetic Foot Ulcer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041672
Enrollment
30
Registered
2022-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Herbal topical spray: Herbal topical spray is a unique alkaline formulation. It is a combination of extracts of herbs and natural amino sugars and natural adjuvants. The unique Herbal T

Sponsors

Inzpera Healthsciences Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male/female of >=18 and 2.Patient who can and willing to provide written Informed Consent. 3. Patient with a history of type 2 diabetes mellitus 4. 4.Patient having Random Blood Sugar [RBG] Ë? 250 mg/dL, on standard antidiabetic treatment. 5. Patient having glycosylated hemoglobin (HbA1c) of less than 12% (based on the existing reports). 6.Patient with at least ONE but not more than THREE DFU with wound surface area measured between 1 cm2 and 12 cm2 and depth post-debridement between 1cm2 -2cm2 , on the day of randomization (wound surface area measured by greatest length, greatest width). 7.Patient with ulcer located at or below malleolar region of foot and Superficial ulcer, Ulcer without infection, mild and moderate infection. Stage I-A, II-A or I-B on University of Texas wound classification system.

Exclusion criteria

Exclusion criteria: 1.Patient Ë? 18 or Ë? 75 years of age. 2. Pregnant and/or nursing woman. 3. Patient with more than 3 ulcers. 4. Patient with ulcers measuring wound surface area more than 12 cm2 and depth more than 2cm2. 5. Patient having severe or poorly controlled Type II diabetes mellitus with severe hyperglycemia (RBG more than 250 mg/dL). 6. Patient having HbA1c of more than 12%. 7. Patient with severe ischemia with Ankle-Brachial Index (ABI) 8. Patient having progressive weight loss. 9. Patient having poor nutritional status (S. albumin less than 2.5g /dL). 10. Patient with ulcer deep into bone and joint or Osteomyelitis or Severe ulcer.

Design outcomes

Primary

MeasureTime frame
Percentage of subjects with complete healing of ulcer. Complete healingâ?? will be defined as absence of visible wound by complete epithelialization.[Time Frame: 10 weeks ]Timepoint: 10 weeks

Secondary

MeasureTime frame
1. Time taken for achieving complete wound closure from the baseline [Time Frame: 10 weeks ] 2. Change in wound surface area from baseline [ Time Frame: 10 weeks ] Mean percent change in wound area from baseline at each visitTimepoint: 10 weeks

Countries

India

Contacts

Public ContactDivya C

Bioagile Therapeutics Pvt. Ltd

divya@bioagiletherapeutics.com9538961761

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026